ZA983548B - Controlled release of drugs delivered by sublingual or buccal administration - Google Patents

Controlled release of drugs delivered by sublingual or buccal administration

Info

Publication number
ZA983548B
ZA983548B ZA983548A ZA983548A ZA983548B ZA 983548 B ZA983548 B ZA 983548B ZA 983548 A ZA983548 A ZA 983548A ZA 983548 A ZA983548 A ZA 983548A ZA 983548 B ZA983548 B ZA 983548B
Authority
ZA
South Africa
Prior art keywords
sublingual
controlled release
buccal administration
drugs delivered
drugs
Prior art date
Application number
ZA983548A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of ZA983548B publication Critical patent/ZA983548B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA983548A 1997-04-29 1998-04-28 Controlled release of drugs delivered by sublingual or buccal administration ZA983548B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/841,250 US5888534A (en) 1995-06-13 1997-04-29 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
ZA983548B true ZA983548B (en) 1999-01-28

Family

ID=25284405

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA983548A ZA983548B (en) 1997-04-29 1998-04-28 Controlled release of drugs delivered by sublingual or buccal administration

Country Status (23)

Country Link
US (1) US5888534A (de)
EP (1) EP1017371B1 (de)
JP (1) JP4948691B2 (de)
CN (1) CN1135103C (de)
AR (1) AR012615A1 (de)
AT (1) ATE244000T1 (de)
BR (1) BR9808703A (de)
CA (1) CA2289260C (de)
CO (1) CO4940397A1 (de)
CZ (1) CZ292513B6 (de)
DE (1) DE69816103T2 (de)
DK (1) DK1017371T3 (de)
ES (1) ES2201487T3 (de)
HK (1) HK1031334A1 (de)
HU (1) HU225108B1 (de)
IL (1) IL132646A0 (de)
NO (1) NO995302L (de)
NZ (1) NZ501114A (de)
PL (1) PL336759A1 (de)
PT (1) PT1017371E (de)
TW (1) TW430562B (de)
WO (1) WO1998048781A1 (de)
ZA (1) ZA983548B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
IL155667A0 (en) * 2000-11-15 2003-11-23 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
CN100562317C (zh) * 2001-10-17 2009-11-25 武田药品工业株式会社 含大量酸不稳定药物的颗粒
ES2271542T3 (es) * 2002-02-07 2007-04-16 Pharmacia Corporation Forma de dosificacion farmaceutica para administracion por la mucosa.
CA2479372A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
KR20080039400A (ko) * 2005-07-07 2008-05-07 파남 컴퍼니스 인크. 고수용성 약물의 서방성 약학 조성물
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US8747005B2 (en) * 2008-06-04 2014-06-10 Colgate-Palmolive Company Oral care implement with cavitation system
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN101475145B (zh) * 2009-01-20 2014-10-22 同济大学 一种具有磁热和靶向药物缓释特性的水滑石及其制备方法
PL2952191T3 (pl) 2009-06-12 2019-02-28 Sunovion Pharmaceuticals Inc. Apomorfina w postaci do podawania podjęzykowego
JP2013503853A (ja) * 2009-09-04 2013-02-04 ムニセクハー メダサニ， 神経変性または神経・筋変性疾患の治療方法およびその治療薬
EP2504019A2 (de) 2009-11-25 2012-10-03 ArisGen SA Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion
WO2012083269A1 (en) * 2010-12-16 2012-06-21 Cynapsus Therapeutics, Inc. Sublingual films
EP3939569A1 (de) 2011-09-19 2022-01-19 Orexo AB Neue missbrauchssichere pharmazeutische zusammensetzung zur behandlung von opiatsucht
US20140256822A1 (en) * 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2018112061A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
WO2020243538A1 (en) * 2019-05-31 2020-12-03 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
PT758895E (pt) * 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
EP1017371A4 (de) 2000-07-12
EP1017371B1 (de) 2003-07-02
EP1017371A1 (de) 2000-07-12
HUP0003405A3 (en) 2001-04-28
BR9808703A (pt) 2001-11-20
HUP0003405A2 (hu) 2001-02-28
JP2001527546A (ja) 2001-12-25
ES2201487T3 (es) 2004-03-16
DE69816103D1 (de) 2003-08-07
NO995302D0 (no) 1999-10-29
CN1271276A (zh) 2000-10-25
CZ292513B6 (cs) 2003-10-15
NZ501114A (en) 2001-09-28
HK1031334A1 (en) 2001-06-15
US5888534A (en) 1999-03-30
WO1998048781A1 (en) 1998-11-05
NO995302L (no) 1999-12-27
DE69816103T2 (de) 2004-04-15
CZ386099A3 (cs) 2000-04-12
PL336759A1 (en) 2000-07-17
AR012615A1 (es) 2000-11-08
JP4948691B2 (ja) 2012-06-06
CO4940397A1 (es) 2000-07-24
CA2289260C (en) 2008-02-12
CA2289260A1 (en) 1998-11-05
IL132646A0 (en) 2001-03-19
TW430562B (en) 2001-04-21
CN1135103C (zh) 2004-01-21
PT1017371E (pt) 2003-10-31
HU225108B1 (en) 2006-06-28
DK1017371T3 (da) 2003-09-29
ATE244000T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
ZA983548B (en) Controlled release of drugs delivered by sublingual or buccal administration
EG23875A (en) Oral pharmaceutical pulsed release dosage form
EP1043030A4 (de) Medizinische zusammensetzungen mit verzögerter wirkstoffabgabe
PL341428A1 (en) Oral pharmacological dosage form of prolonged release type
GB2341550B (en) Gastroretentive controlled release microspheres for improved drug delivery
AU2827095A (en) Controlled release oral drug delivery system
AU3977099A (en) Controlled release oral dosage form
AU5914999A (en) Controlled release drug delivery
PL344039A1 (en) Sustained release drug delivery devices
ZA986889B (en) Controlled release pharmaceutical compositions containing tiagabine
HK1019142A1 (en) Drug composition with controlled drug release rate
AU7578598A (en) Controlled release dosage forms containing water soluble drugs
IL138192A0 (en) Controlled release oral dosage forms
EP1171134A4 (de) Gesteuerte freisetznug von sublingual oder bukkal verabreichten sildenafil
HUP0202744A3 (en) Oral controlled release formulations containing rivastigmine
AU9587198A (en) Immediate release drug delivery forms
EP1007125A4 (de) Steuerung der gas- oder arzneimittelverabreichung zu einem patienten
SI1017371T1 (en) Controlled release of drugs delivered by sublingual or buccal administration
SI0833619T1 (en) Controlled release of drugs delivered by sublingual or buccal administration
SI1043977T1 (en) Oral pharmaceutical pulsed release dosage form
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
SI1216032T1 (sl) Oralne formulacije s kontroliranim sproščanjem